{"name":"Spine BioPharma, Inc","slug":"spine-biopharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"SB-01 For Injection","genericName":"SB-01 For Injection","slug":"sb-01-for-injection","indication":"Spinal fusion","status":"phase_3"},{"name":"Sham Needle","genericName":"Sham Needle","slug":"sham-needle","indication":"Clinical trials for various conditions","status":"phase_3"}]}],"pipeline":[{"name":"SB-01 For Injection","genericName":"SB-01 For Injection","slug":"sb-01-for-injection","phase":"phase_3","mechanism":"SB-01 For Injection is a bone graft substitute used to promote bone growth and healing.","indications":["Spinal fusion"],"catalyst":""},{"name":"Sham Needle","genericName":"Sham Needle","slug":"sham-needle","phase":"phase_3","mechanism":"Sham Needle is used to create a placebo effect in clinical trials.","indications":["Clinical trials for various conditions"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxNWE13UWg0d1UtcXpDY1BhTEwtNFUzU0pxWC1PcDgySUsxblBXai1aSkdrNmphaUtEQVRrVi04VzBGMUwwaG9YYVFiUGpoR0JFWTNaYldhWENyX3ZWRHJDSC1jdU5uM2FfN2Y3YkpHTVQ5VzVub2I1QUI3X3Frd3k3MndoU3k4eFIyNG5hT2JGNElYV1pMRzFyeU1kZmlhYlp0RG1IYmlIQkdmQmY4bjZ4UHkzaklVVTVETVVuZHlhQXJlUGRPWFVGeFRSa1dDVHdiOXV3cWJVenlUQWZpN3VFbk1RVXZPbFRzelNVZg?oc=5","date":"2026-04-02","type":"pipeline","source":"Barchart.com","summary":"Chronic and Acute Pain Treatment Pipeline Shows Strong Momentum as 180+ Pharma Companies in the Race | DelveInsight - Barchart.com","headline":"Chronic and Acute Pain Treatment Pipeline Shows Strong Momentum as 180+ Pharma Companies in the Race | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1IWGt0aHk5LV9Ra2l3Z2FqQXB5am1RODZZaVIydHJvM2ZMX2R6bFJ4R0VGWjAwU25CdkYzY1VocnAwcGpTcnJTNXhYVU9zanB6Sk5pbE9NVk1OMURLeHM3VEdkWGRlcnPSAWxBVV95cUxOV05WRWNUVmU1Zy1QRzNXQlBwQjlUb2xieU91ekx1SmNQcXEwQ2dxVkxtaThLd21uUzFiaE1pWEVZVVJ3dUQ1RjNTelpyb3hyLVlHa3ZyT3Y5c0ZTQUM2MFRaTFNEYkp2X2E0N3c?oc=5","date":"2026-03-05","type":"pipeline","source":"BioInformant","summary":"The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant","headline":"The Pipeline for iPSC-Derived Cell Therapeutics in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxPbTQ4dFNtN3ZWMHZHY1NwMmgzbVZvVzF0VElQNWVWWXVHQ1BjTXIxTmQ4VWY4RGdfVlFVYkU0LVBPbHZJQThMQmRHRGFYc19yYXZOeFJVSjh2UFNoR2hfT0tHZmZYdmdpVDJlOWtnQklZSERqdWxidWtvVjJCLWQyMVladEh4b0hsZ0lXZGRkWXFsc1FLU1hjWkdDdmx3WmNSQ0FfT1FGcmIxejI3Rnk3LWpCbm8yNS0xQmUtVFRsajhtTHdrWkZ6S3gwNTNxd1cxTkE3RWZnS2t6V3FLY2FUN2JQbGRrVWlMY1kzRkdRcUVVMms3WUhPQnhCbkwzeWxsRnFva0oyVEVjdUx6ZTAycFBQakh0dXVSRENRb2hfTjBoNEtUOTZGdGtNem5nemJBaEQ0elRhT245eG9H?oc=5","date":"2026-01-28","type":"trial","source":"globenewswire.com","summary":"Chronic and Acute Pain Clinical Trial Pipeline Analysis: - globenewswire.com","headline":"Chronic and Acute Pain Clinical Trial Pipeline Analysis:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQMUZiUDFCMDdfNzZkR1J1bEFoX3JaRnBESG0xd0FYSnNoVlFCRWlzcjhLanczUnoxN1NlaFhUUC1xa3ZZWDFLVzZuNFF3bzVUbkJETHZueVZuUHhIYUlob1k2U2x3QWtfVVMwODg5TXYtckdOaVNHTVBVbmJacEVoVlJtd3FweGpLaEFQTFIzTWQxWTE0Mjh1SDBhU1FFdkVINXJSMWtVT0s?oc=5","date":"2025-09-29","type":"trial","source":"BioWorld News","summary":"Phase III successes in August include Sjögren’s, myasthenia gravis - BioWorld News","headline":"Phase III successes in August include Sjögren’s, myasthenia gravis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNZGZCaENKdzc0UTdLSFRORWdEWUwtTjc4b0htbkttYldpaDVDTTlYUWhxTXFZa0sxWjBYcURySjFtMERKcUt2QkRrYlI4cHZFZ0dKdG1PcDZRNDA1b3VHMTdHZDRVenl5V0Z1ZWpSeWtDUmR3M1A3cllONFZYTUhBOTlEOExQQnhkRDRVNFRYQnl5WjZhQmdlbWpwZGV3Z3FYb1lJM3doTUdwd3dreERwWDA0aUU1NE0?oc=5","date":"2025-09-23","type":"regulatory","source":"BioPharma Dive","summary":"Scholar Rock SMA drug rejected by FDA over manufacturing concerns - BioPharma Dive","headline":"Scholar Rock SMA drug rejected by FDA over manufacturing concerns","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE9PWm9rQnUzVDdFSEdhS1dSREczNVdRVUxERFRvd3dxb2RnTS15R0JrNUpmd1JETVotdThaRzBEem1Sb0FYRDNHcGJjdHNpWXFxdlNEeFBvZ0drblM0RzM3cXl2OXlUUWhxbVp2S0FLRVo?oc=5","date":"2025-08-04","type":"trial","source":"Clinical Trials Arena","summary":"Spine BioPharma’s trial of SB-01 fails to meet primary endpoint - Clinical Trials Arena","headline":"Spine BioPharma’s trial of SB-01 fails to meet primary endpoint","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOY0h4VDF0Ym1FUkNaZ0VISUtmcC1kaVRUakd5ZldlMnB1bk1FMFNORl9jcExMZXRlanlRWGNIS0YyTnpTTk53X2NmWDJOVndMTzVya3R6b2F4bk9meW03b29DellJWlVObllkeGdvbUs5TEZWc0Z3WjB3Nm5uOTRSSU1xcmJJak9Md2JLSEI1aEo1NkN2bnNTTXpLUlVVNDFv?oc=5","date":"2025-08-04","type":"trial","source":"BioWorld News","summary":"Sham response variability mars Spine’s phase III pain trial - BioWorld News","headline":"Sham response variability mars Spine’s phase III pain trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNdE9sVVNtNVJSb3Y2WlIxV2lOMUdEYllFZ0ZlY0paZlA5U1pCNEF4T0lMNTN4Sk1CMUJZMXpFSG5DUUpFRVJBaElhWFNMbXV1SFpWTklOdjNraWx0cHVZUkFiaFUxZ3FBekJqcFBoTldMQURFc2ZSM2lCS0NZSHBLUTY5SVpZamlsOXc0bmlKaHcxRnEzYl9NOUZrSThiYi1xWEZOeWRwUFdjV0N5MlBfUlZnRy1hNVRXX0EwSkdzT3A2Q1hmOFJOX0tuMTVwN0dyN2txdTNYSmhnN0NwdFY5d3FFTW9PM1czNmtDSEdMcTQwXzBLSVh2YmZFZTF2M2YzTmlBVUxBRU44VzhuaGJwSjVkY1pxV0tVYlJKcjd5bVkwR0RHTFItVExLdzNReHJGTk43TjRUTQ?oc=5","date":"2025-08-01","type":"trial","source":"Business Wire","summary":"Spine BioPharma Announces Topline Results from Phase 3 MODEL Trial For SB-01 (vicatertide) In Chronic Low Back Pain Associated with Degenerative Disc Disease - Business Wire","headline":"Spine BioPharma Announces Topline Results from Phase 3 MODEL Trial For SB-01 (vicatertide) In Chronic Low Back Pain Asso","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPcmNFaVp6aW1ENzR1eEt4eF9RZm5oZE05a3YyYVFfM05JYlF1UExiN0d4aHZlMGxlNi00OVd4SWJfVXFPc0I3TWZoVHhZYTBYeV9uUEY2T2hmSUN0YUtwWk5kYzJDcmpSUFJrVERGcmQ3eXpHdkhyRmxmckZYcG9NZ0JnOVdPLUNhLTYtWkZVSDlMaklXenY2SGdBYTRLMUZrTldIUzNURlhpTklsSUlUQV9LMmJQN2hYQVEyanhn?oc=5","date":"2025-08-01","type":"trial","source":"Fierce Biotech","summary":"Spine BioPharma misses primary endpoint in back pain phase 3, blames sham response rate - Fierce Biotech","headline":"Spine BioPharma misses primary endpoint in back pain phase 3, blames sham response rate","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxQNU1DUUt4ZjloenhrejJxSGVlMHFWMGxlUk0tTjBOM3RCZ0RSRTkxMElaanF0U0dMQk5CX2FpX2hkQXNRVElRSzNYaDZ4UjZ0d2tuUzVMZjFodTlQLVJBTWpnSzNwM19xS1BPOWg0T0NKcDQ5SWwwNFhYVi1BbTlXc1A1NTlRX3YwcVYwOHl3MUF1YjktSGlFbk1RNVF0c0ZUNG5kdzJBN00ta2NOMUtSc3g5Y281ZXhoaGxncDFJSjQzVFdua2gta3pfdUJkam5tRzBKSlQ1MUdtYlE1WHJmQzlQbFJ5Uk8wcWhIUHlpUXBZS0VaZFpHZQ?oc=5","date":"2024-09-24","type":"trial","source":"BioSpace","summary":"Spine BioPharma, Inc. Announces Completion of Enrollment for Phase 3 Clinical Trial of SB-01 to Address Chronic Low Back Pain - BioSpace","headline":"Spine BioPharma, Inc. Announces Completion of Enrollment for Phase 3 Clinical Trial of SB-01 to Address Chronic Low Back","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxPb1hHUEU4bTVxNFRJV1NqUXZ6Qk1xZnNteldQWGZEdnlkN0RBcXJFblRQNDZ0TkduaUJUeFN2MmMycmpENnNEeDhsYWJoMjhYVkN4bzFMQU1Nck5Ka1ZSOC1fT21vei1sWXZKTTVrb1hJMGlVN21TTm1DVXRrcjl2ekU5ZUNGLVZzaHBzck4wOEpZYW5MTWEzVG96bmRxODVZX3BSaEsxNzhrMkVaMkdDSmpoVkhZcDRIR2Z6MEFoS19HLWFNeXkxVzYyV19aVUJxRWM3QXhudjZDV2xOZ245TVNTTGQyVnhBS052ZS1nWS13MDdVWGR3VjNEenE?oc=5","date":"2024-07-10","type":"pipeline","source":"PR Newswire","summary":"Spine BioPharma, Inc. Announces Agreement with Ensol BioSciences, Inc. to Expand Indications for SB-01 For Injection - PR Newswire","headline":"Spine BioPharma, Inc. Announces Agreement with Ensol BioSciences, Inc. to Expand Indications for SB-01 For Injection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQOFR3d2o3aDJmMEIxWDNsME5YT0djQTZPZ3NMS2pUUkE2TUdyY1ZBNHNKQnpJZVJzalJYazAwX1V1aEpYVFg2QmdsRmhrUGtGMUhkTjlnQV8wY3ZTWXBBQ2dxR1NHaU11bkZmUzZXbTNtMUNTclllaW5id2xZM3E3bDNZRExLUFdNeE5LLVFiMFp5TkE?oc=5","date":"2023-01-11","type":"pipeline","source":"Fortune Business Insights","summary":"Degenerative Disc Disease Treatment Market Size, Share, 2034 - Fortune Business Insights","headline":"Degenerative Disc Disease Treatment Market Size, Share, 2034","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}